文章：

PAK家族激酶在急性髓系白血病中的预后意义

Prognostic significance of PAK family kinases in acute myeloid leukemia 

原文发布日期：2019-03-20 

英文摘要：

Acute myeloid leukemia (AML) is a clonal and heterogeneous disease characterized by a myriad of genetic defects. Genetic abnormalities are powerful prognostic factors. P21-activated kinases (PAKs) are a kind of serine/threonine protein kinases, which is regulator of plenty of oncogenic signaling pathways. The clinical and prognostic value of PAKs in AML is unclear. A total of 155 AML patients with PAK expression data from The Cancer Genome Atlas database were enrolled in this study. Eighty-four patients underwent chemotherapy only, 71 also underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT). In the chemotherapy-only group, high PAK3 and PAK7 expression were both bound up with poor EFS and OS (all P < 0.05). However, high PAK2 expressers had better EFS and OS (all P < 0.05). Multivariate analysis demonstrated that high PAK7 expression was an adverse independent prognostic factor in patients who received chemotherapy only. PAKs have no influence in EFS and OS in patients who underwent allo-HSCT. In conclusion, high PAK2 expression is a favorable prognostic factor, as to the high expression of PAK3 and PAK7, they are poor prognostic factors, and PAK7 has better prognostic value, but their prognostic effects can be offset by allo-HSCT. 

摘要翻译： 

急性髓系白血病（AML）是一种具有多种遗传异常特征的克隆性异质性疾病。遗传异常是重要的预后因素。P21激活激酶（PAKs）作为丝氨酸/苏氨酸蛋白激酶家族，是多条致癌信号通路的调控因子，但其在AML中的临床及预后价值尚不明确。本研究从癌症基因组图谱数据库中纳入155例具有PAK表达数据的AML患者，其中84例仅接受化疗，71例额外接受了异基因造血干细胞移植（allo-HSCT）。在单纯化疗组中，高表达的PAK3和PAK7均与较差的无事件生存期（EFS）和总生存期（OS）相关（均P<0.05），而高表达PAK2患者则表现出更优的EFS和OS（均P<0.05）。多因素分析证实，高表达PAK7是单纯化疗患者的独立不良预后因素。在allo-HSCT治疗组中，PAKs表达对EFS和OS无显著影响。结论：高表达PAK2是有利预后因素，PAK3和PAK7高表达则提示不良预后（其中PAK7具有更优的预后预测价值），但allo-HSCT可逆转这些PAKs的预后效应。

原文链接：

Prognostic significance of PAK family kinases in acute myeloid leukemia